News | 10.12.2021
KONGRESSBERICHT SAN ANTONIO BREAST CANCER SYMPOSIUM 2021
Nadia Harbeck spricht über Studie DESTINY-Breast11
Nadia Harbeck, MD, PhD, speaks about open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)